"Lunit is poised to evolve from an Al-based medical imaging company into a pioneering provider of Al healthcare platform"

Lunit Inc, a pioneering player in South Korea’s medical imaging industry, achieved significant milestones in 2023. The company secured the EU MDR mark and unveiled its cutting-edge 3D breast screening product, known as ‘Lunit INSIGHT DBT.’ Notably, Lunit’s AI technology has been adopted by over 2,000 healthcare institutions worldwide, marking a major accomplishment. Lunit made noteworthy announcements, including their expansion into Saudi Arabia and Europe. Brandon Suh, the CEO of Lunit Inc., shares more about the company’s mission to combat cancer and advance medical image analytics. Edited excerpts;

- Ayesha Siddiqui

Can you provide a brief overview of Lunit’s mission and its core focus in the field of medical AI? 

Lunit is a medical AI company with a mission to conquer cancer. The company’s core focus is on developing AI solutions for precision diagnostics and therapeutics. This includes AI-powered tools for cancer screening and diagnosis, and AI-powered biomarkers that can enable new therapeutic development and then accurately guide patients to specific cancer therapies. By ensuring timely diagnosis and effective treatment for each patient, Lunit aims to increase the chance of survival by detecting early-stage cancers and helps increase immunotherapy efficacy by accurately predicting treatment response.

Lunit has received recognition in international AI competitions, even surpassing tech giants. What do you believe sets Lunit apart from the competition?